Group B Streptococcus (GBS) is an important perinatal pathogen. Because transplacentally acquired maternal antibodies to the GBS capsular polysaccharides (CPS) confer protection, prevention of infant disease may be possible after immunization of women. Unfortunately, the purified CPS of GBS are only variably immunogenic in adults; therefore to enhance immunogenicity we have designed and developed a CPS-protein conjugate vaccine. The lability of a conformationally dependent epitope on the III CPS containing a critical sialic acid residue was important to consider in vaccine design. 100 women were randomized to receive GBS type III CPS-tetanus toxoid conjugate (III-TT) vaccine at one of three doses; unconjugated GBS type III CPS; or saline. Serum samples were obtained before immunization and 2, 4, 8, and 26 wk thereafter, and specific antibody to type III CPS was measured. Vaccines were well tolerated. In sera from recipients of the highest dose of III-TT, CPS-specific IgG levels rose from a geometric mean of 0.09 microg/ml before immunization to 4.53 microg/ml 8 wk later, whereas levels in recipients of unconjugated type III CPS rose from 0.21 microg/ml to 1.41 microg/ml. Lower doses resulted in lower antibody levels. A > or = 4-fold rise in antibody concentration was achieved in 90% of recipients of III-TT compared with 50% of those that received III CPS (P = 0.0015). Antibodies evoked by the conjugate vaccine recognized a conformationally dependent epitope of the III-CPS, promoted opsonophagocytosis and killing of GBS, and, after maternal immunization, protected neonatal mice from lethal challenge with type III GBS. We conclude that directed coupling of type III GBS polysaccharide to a carrier protein yielded a conjugate vaccine with preserved expression of a highly labile conformational epitope involving sialic acid and enhanced immunogenicity compared with uncoupled CPS.
D L Kasper, L C Paoletti, M R Wessels, H K Guttormsen, V J Carey, H J Jennings, C J Baker
Title and authors | Publication | Year |
---|---|---|
Serotypes and clinical manifestations of invasive group B streptococcal infections in western Sweden 1998-2001
E Persson, S Berg, B Trollfors, P Larsson, E Ek, E Backhaus, BE Claesson, L Jonsson, G Radberg, T Ripa, S Johansson |
Clinical Microbiology and Infection | 2004 |
Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria
MY Richter, H Jakobsen, A Birgisdottir, JF Haeuw, UF Power, GD Giudice, A Bartoloni, I Jonsdottir |
Infection and immunity | 2004 |
Increased sensitivity of a latex agglutination method for serotyping group B streptococcus
JA Elliott, TA Thompson, RR Facklam, HC Slotved |
Journal of clinical microbiology | 2004 |
Polysaccharide processing and presentation by the MHCII pathway
BA Cobb, Q Wang, AO Tzianabos, DL Kasper |
Cell | 2004 |
Significance, management and prevention of Streptococcus agalactiae infection during the perinatal period
R Berner |
Expert Review of Anti-infective Therapy | 2004 |
Polysaccharide Processing and Presentation by the MHCII Pathway
BA Cobb, Q Wang, AO Tzianabos, DL Kasper |
Cell | 2004 |
Perinatal Infections Due to Group B Streptococci
RS Gibbs, S Schrag, A Schuchat |
Obstetrics & Gynecology | 2004 |
Vacunas y embarazo (y II): la protección del recién nacido mediante la vacunación de la embarazada
J Puig-Barberà |
Atención Primaria | 2004 |
Vaccines against bacterial meningitis
S Segal, AJ Pollard |
British Medical Bulletin | 2004 |